Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Levin

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Arthritis Care & Research|February 16, 2026
Treatment Sequencing and Line of Therapy for Biologics and JAK inhibitors in Rheumatoid Arthritis Patients: Implications for Design and Uptake of New Drugs and Predictive Biomarker DiagnosticsJeffrey R Curtis, Shanette Daigle, Emily E Holladay, et al.
Frontiers in Immunology|February 27, 2024
Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine developmentYi Wang, Matthew C Troutman, Carl Hofmann, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 20, 2020
Anti-PEG IgE in anaphylaxis associated with polyethylene glycolZhao-Hua Zhou, Cosby A Stone, Baruch Jakubovic, et al.
Journal of Translational Autoimmunity|May 6, 2022
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosusChristie Fanton, Richard Furie, Vishala Chindalore, et al.
The Journal of Rheumatology|April 16, 2022
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE StudyTien Nguyen, Melvin Churchill, Robert Levin, et al.
Schizophrenia Bulletin|May 13, 2005
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophreniaRobert W Buchanan, Miriam Davis, Donald Goff, et al.
Journal of Pharmaceutical Sciences|October 3, 2009
Topical delivery of lycopene using microemulsions: enhanced skin penetration and tissue antioxidant activityLuciana B Lopes, Hillary VanDeWall, Hsin T Li, et al.
Integrative Cancer Therapies|November 21, 2009
Circadian clock manipulation for cancer prevention and control and the relief of cancer symptomsWilliam J M Hrushesky, James Grutsch, Patricia Wood, et al.
Annals of the Rheumatic Diseases|July 30, 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyJoan T Merrill, Daniel J Wallace, Michelle Petri, et al.
Arthritis Research & Therapy|June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritisStanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Arthritis Care & Research|February 16, 2026
Treatment Sequencing and Line of Therapy for Biologics and JAK inhibitors in Rheumatoid Arthritis Patients: Implications for Design and Uptake of New Drugs and Predictive Biomarker DiagnosticsJeffrey R Curtis, Shanette Daigle, Emily E Holladay, et al.
Frontiers in Immunology|February 27, 2024
Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine developmentYi Wang, Matthew C Troutman, Carl Hofmann, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 20, 2020
Anti-PEG IgE in anaphylaxis associated with polyethylene glycolZhao-Hua Zhou, Cosby A Stone, Baruch Jakubovic, et al.
Journal of Translational Autoimmunity|May 6, 2022
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosusChristie Fanton, Richard Furie, Vishala Chindalore, et al.
The Journal of Rheumatology|April 16, 2022
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE StudyTien Nguyen, Melvin Churchill, Robert Levin, et al.
Schizophrenia Bulletin|May 13, 2005
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophreniaRobert W Buchanan, Miriam Davis, Donald Goff, et al.
Journal of Pharmaceutical Sciences|October 3, 2009
Topical delivery of lycopene using microemulsions: enhanced skin penetration and tissue antioxidant activityLuciana B Lopes, Hillary VanDeWall, Hsin T Li, et al.
Integrative Cancer Therapies|November 21, 2009
Circadian clock manipulation for cancer prevention and control and the relief of cancer symptomsWilliam J M Hrushesky, James Grutsch, Patricia Wood, et al.
Annals of the Rheumatic Diseases|July 30, 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyJoan T Merrill, Daniel J Wallace, Michelle Petri, et al.
Arthritis Research & Therapy|June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritisStanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
Pageof 6